National Pension Service Purchases 114,105 Shares of Abbott Laboratories $ABT

National Pension Service grew its position in shares of Abbott Laboratories (NYSE:ABT) by 2.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,208,467 shares of the healthcare product maker’s stock after acquiring an additional 114,105 shares during the quarter. National Pension Service’s holdings in Abbott Laboratories were worth $381,876,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of the company. MidAtlantic Capital Management Inc. acquired a new stake in Abbott Laboratories in the 4th quarter valued at $25,000. Cornerstone Financial Management LLC bought a new position in shares of Abbott Laboratories in the fourth quarter valued at $25,000. Purpose Unlimited Inc. acquired a new position in shares of Abbott Laboratories during the fourth quarter valued at about $25,000. Portfolio Resources Advisor Group Inc. bought a new stake in shares of Abbott Laboratories during the fourth quarter worth about $26,000. Finally, Abound Financial LLC acquired a new stake in shares of Abbott Laboratories in the 4th quarter worth about $26,000. 75.18% of the stock is owned by institutional investors and hedge funds.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: The FDA approved Abbott’s TactiFlex Duo Ablation Catheter, Sensor Enabled, for treating challenging cases of atrial fibrillation. The catheter combines pulsed-field ablation (PFA) and radiofrequency (RF) energy, giving physicians greater flexibility and expanding Abbott’s cardiac rhythm-management portfolio. The device previously received a European CE mark in January 2026, and U.S. approval could support broader adoption and future revenue growth. Abbott’s dual ablation catheter lands FDA approval
• Positive Sentiment: TD Cowen reaffirmed its “buy” rating on Abbott and maintained a $135 price target, indicating substantial potential upside from recent trading levels. The endorsement suggests the firm views Abbott’s product pipeline and long-term fundamentals favorably. TD Cowen reaffirms Abbott buy rating
• Neutral Sentiment: A comparison of Abbott and Envista focuses on which medical-products stock offers better value. Abbott’s established business and growth prospects remain attractive, but its valuation may make it less compelling to investors specifically seeking undervalued shares. NVST or ABT: Which Is the Better Value Stock Right Now?
• Neutral Sentiment: Abbott was highlighted as a potential defensive “Dividend King,” supported by a 54-year dividend-growth streak and healthcare-related catalysts. This may appeal to income-focused investors, although the article is general commentary rather than a new company announcement. If a Stock Market Crash Is Coming, Investors Will Want to Own This Dividend King
• Negative Sentiment: Abbott recently underperformed the broader market in a prior session, reflecting near-term selling pressure. The decline appears market- or sentiment-driven rather than tied to a deterioration in the company’s fundamentals, but it may be tempering the immediate reaction to the FDA news. Here’s Why Abbott Fell More Than the Broader Market

Abbott Laboratories Price Performance

Abbott Laboratories stock opened at $105.29 on Thursday. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $137.49. The company’s 50 day moving average price is $105.30 and its two-hundred day moving average price is $99.90. The stock has a market cap of $182.19 billion, a P/E ratio of 34.07, a P/E/G ratio of 1.96 and a beta of 0.59. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.03. The company had revenue of $12.59 billion during the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.Abbott Laboratories’s quarterly revenue was up 13.0% on a year-over-year basis. During the same period in the prior year, the company posted $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, equities analysts predict that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th were paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date was Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is 81.55%.

Analyst Ratings Changes

ABT has been the subject of a number of analyst reports. Robert W. Baird assumed coverage on Abbott Laboratories in a research note on Wednesday, July 1st. They set an “outperform” rating and a $121.00 price target for the company. Citigroup increased their price objective on Abbott Laboratories from $108.00 to $112.00 and gave the stock a “buy” rating in a research note on Friday, July 17th. The Goldman Sachs Group cut their target price on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating on the stock in a research report on Wednesday, May 27th. Wolfe Research upgraded Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price target for the company in a report on Thursday, August 13th. Finally, Royal Bank Of Canada restated an “outperform” rating and set a $130.00 price objective on shares of Abbott Laboratories in a research note on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $119.50.

About Abbott Laboratories

Abbott Laboratories (NYSE: ABT) is a global healthcare company that develops, manufactures and sells medical products and technologies. Its operations span four principal areas: medical devices, diagnostics, established pharmaceutical products and nutrition. Abbott serves healthcare providers, institutions and consumers in markets around the world.

The company’s medical device portfolio includes products for cardiovascular care, diabetes management and other specialties. Its diagnostics business provides laboratory systems, tests and point-of-care solutions, while its nutrition products include infant, child and adult nutritional offerings sold under brands such as Similac, Ensure and Pedialyte.